Free Trial

Smith & Nephew SNATS (SNN) Stock Price, News & Analysis

Smith & Nephew SNATS logo
$30.26 +0.10 (+0.33%)
As of 07/3/2025 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Smith & Nephew SNATS Stock (NYSE:SNN)

Key Stats

Today's Range
$30.13
$30.28
50-Day Range
$26.76
$30.67
52-Week Range
$23.69
$31.72
Volume
274,870 shs
Average Volume
808,053 shs
Market Capitalization
$13.25 billion
P/E Ratio
14.01
Dividend Yield
2.94%
Price Target
$28.00
Consensus Rating
Hold

Company Overview

Smith & Nephew SNATS Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

SNN MarketRank™: 

Smith & Nephew SNATS scored higher than 75% of companies evaluated by MarketBeat, and ranked 246th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Smith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Smith & Nephew SNATS has only been the subject of 3 research reports in the past 90 days.

  • Read more about Smith & Nephew SNATS's stock forecast and price target.
  • Earnings Growth

    Earnings for Smith & Nephew SNATS are expected to grow by 18.34% in the coming year, from $1.69 to $2.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Smith & Nephew SNATS is 14.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Smith & Nephew SNATS is 14.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.64.

  • Price to Earnings Growth Ratio

    Smith & Nephew SNATS has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Smith & Nephew SNATS has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Smith & Nephew SNATS's valuation and earnings.
  • Percentage of Shares Shorted

    0.57% of the float of Smith & Nephew SNATS has been sold short.
  • Short Interest Ratio / Days to Cover

    Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Smith & Nephew SNATS has recently decreased by 14.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Smith & Nephew SNATS pays a meaningful dividend of 2.95%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Smith & Nephew SNATS does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Smith & Nephew SNATS is 41.20%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 44.50% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.

  • Read more about Smith & Nephew SNATS's dividend.
  • Percentage of Shares Shorted

    0.57% of the float of Smith & Nephew SNATS has been sold short.
  • Short Interest Ratio / Days to Cover

    Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Smith & Nephew SNATS has recently decreased by 14.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Smith & Nephew SNATS has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • MarketBeat Follows

    2 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Smith & Nephew SNATS is held by insiders.

  • Percentage Held by Institutions

    Only 25.64% of the stock of Smith & Nephew SNATS is held by institutions.

  • Read more about Smith & Nephew SNATS's insider trading history.
Receive SNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew SNATS and its competitors with MarketBeat's FREE daily newsletter.

SNN Stock News Headlines

Cold War Discovery Could Unlock $100 Trillion in Wealth
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
Smith & Nephew (SN) Receives a Buy from Citi
See More Headlines

SNN Stock Analysis - Frequently Asked Questions

Smith & Nephew SNATS's stock was trading at $24.58 on January 1st, 2025. Since then, SNN shares have increased by 23.1% and is now trading at $30.26.

Smith & Nephew SNATS, Inc. (NYSE:SNN) announced its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.59.

Top institutional investors of Smith & Nephew SNATS include Marotta Asset Management.

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew SNATS investors own include JPMorgan Chase & Co. (JPM), Johnson & Johnson (JNJ), PepsiCo (PEP), Taiwan Semiconductor Manufacturing (TSM), McDonald's (MCD), Sanofi (SNY) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/17/2014
Record date for 5/28 Dividend
3/28/2025
Ex-Dividend for 5/28 Dividend
3/28/2025
Dividend Payable
5/28/2025
Today
7/06/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NYSE:SNN
Employees
17,349
Year Founded
1856

Price Target and Rating

Average Stock Price Target
$28.00
High Stock Price Target
$28.00
Low Stock Price Target
$28.00
Potential Upside/Downside
-7.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
14.01
Forward P/E Ratio
17.91
P/E Growth
0.93
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.81 billion
Cash Flow
$3.16 per share
Price / Cash Flow
9.59
Book Value
$12.04 per share
Price / Book
2.51

Miscellaneous

Free Float
433,593,000
Market Cap
$13.25 billion
Optionable
Optionable
Beta
0.69

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NYSE:SNN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners